25-desacetylrifapentine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
25-desacetylrifapentine
Accession Number
DB15213
Type
Small Molecule
Groups
Investigational
Description

25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).

Structure
Thumb
Synonyms
  • 25-DESACETYL RIFAPENTINE
Categories
UNII
29A0K44SJO
CAS number
79039-56-8
Weight
Average: 835.008
Monoisotopic: 834.441508832
Chemical Formula
C45H62N4O11
InChI Key
LPUNEQQTZOWCNO-WEOUFWGLSA-N
InChI
InChI=1S/C45H62N4O11/c1-23-12-11-13-24(2)44(57)47-35-30(22-46-49-19-17-48(18-20-49)29-14-9-10-15-29)40(54)32-33(41(35)55)39(53)28(6)42-34(32)43(56)45(7,60-42)59-21-16-31(58-8)25(3)37(51)27(5)38(52)26(4)36(23)50/h11-13,16,21-23,25-27,29,31,36-38,50-55H,9-10,14-15,17-20H2,1-8H3,(H,47,57)/b12-11-,21-16-,24-13-,46-22+/t23-,25+,26+,27-,31-,36-,37+,38+,45-/m0/s1
IUPAC Name
SMILES
CO[C@H]1C=CO[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(CC4)C4CCCC4)=C(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@@H]1C)C(O)=C2C(O)=C3C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when 25-desacetylrifapentine is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when 25-desacetylrifapentine is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when 25-desacetylrifapentine is combined with 4-hydroxycoumarin.
AcebutololThe metabolism of Acebutolol can be increased when combined with 25-desacetylrifapentine.
AcenocoumarolThe risk or severity of bleeding can be increased when 25-desacetylrifapentine is combined with Acenocoumarol.
AlprenololThe metabolism of Alprenolol can be increased when combined with 25-desacetylrifapentine.
AnisodamineThe metabolism of Anisodamine can be increased when combined with 25-desacetylrifapentine.
ArotinololThe metabolism of Arotinolol can be increased when combined with 25-desacetylrifapentine.
AtenololThe metabolism of Atenolol can be increased when combined with 25-desacetylrifapentine.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with 25-desacetylrifapentine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
23976039

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentTuberculosis Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:00 / Updated on November 02, 2019 03:31